论文部分内容阅读
目的评价胸腺肽α1联合阿德福韦酯治疗慢性乙型肝炎(CHB)的临床疗效。方法将52例患者分为治疗组、对照组各26例,均给予阿德福韦酯10 mg,每日1次,共1年,治疗组加用胸腺肽α11.6 mg皮下注射,每周2次,共6个月。观察6个月及12个月肝功能、HBV-DNA及HbeAg/HbeAb血清转换。结果治疗组在治疗12个月时,治疗组HBV-DNA阴转率明显优于对照组(P<0.01)。结论胸腺肽α1联合阿德福韦酯在HBV-DNA阴转率方面优于单一用药。
Objective To evaluate the clinical efficacy of thymosin α1 combined with adefovir dipivoxil in the treatment of chronic hepatitis B (CHB). Methods Fifty-two patients were divided into treatment group and control group, with 26 cases in each group. All patients were given adefovir dipivoxil 10 mg once daily for 1 year. The treatment group was treated with subcutaneous injection of thymosin α 11.6 mg Times, a total of 6 months. Liver function, HBV-DNA and HbeAg / HbeAb seroconversion were observed at 6 and 12 months. Results At 12 months of treatment, the negative conversion rate of HBV-DNA in the treatment group was significantly better than that in the control group (P <0.01). Conclusions Thymosin α1 combined with adefovir dipivoxil is superior to single drug in HBV-DNA negative conversion rate.